What are the HIV and STI testing requirements for Pre-Exposure Prophylaxis (PrEP) through the Australian Pharmaceutical Benefits Scheme (PBS)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

HIV and STI Testing Requirements for PrEP in Australia's PBS

HIV and STI testing for PrEP through Australia's Pharmaceutical Benefits Scheme (PBS) requires HIV testing every 3 months, STI screening every 3 months, and kidney function monitoring at baseline and every 6 months.

Initial Testing Requirements Before Starting PrEP

Mandatory Tests

  • HIV testing: A negative HIV test is mandatory before initiating PrEP, preferably using a combination antigen-antibody assay (4th generation test) 1, 2
  • Serum creatinine and estimated glomerular filtration rate: Must be performed within 7 days before starting PrEP 1, 2
  • Hepatitis B surface antigen (HBsAg): Required to assess for active hepatitis B infection 1, 2
  • STI screening: Comprehensive testing for gonorrhea and chlamydia (at all relevant anatomical sites based on sexual practices) and syphilis serology 1
  • Pregnancy test: Required for women before initiating PrEP 2

Additional Baseline Testing

  • Hepatitis C antibody: Recommended, especially for high-risk individuals 1
  • HIV RNA testing: Should be performed if acute HIV infection is suspected 1

Ongoing Monitoring Requirements

HIV Testing

  • Frequency: Every 3 months 1, 2
  • Test type: Laboratory-based HIV antibody and antigen test 1, 2
  • Prescription limits: PrEP prescriptions should not exceed 90 days without interval HIV testing 1

STI Screening

  • Frequency: Every 3 months 1, 2
  • Tests included:
    • Gonorrhea and chlamydia nucleic acid amplification tests (genital and non-genital sites)
    • Syphilis serology
    • Hepatitis C antibody (annually, or more frequently for high-risk individuals) 1

Kidney Function Monitoring

  • Frequency: At least every 6 months 1, 2
  • More frequent monitoring: Required for patients >50 years old, those with baseline creatinine clearance <90 mL/min, or those with hypertension or diabetes 1

Special Considerations

First Follow-up Visit

  • A follow-up visit 30 days after PrEP initiation is recommended for:
    • HIV testing
    • Assessment of adverse effects
    • Adherence support 1

Rapid PrEP Initiation

  • If a negative HIV test result is available from within the past 7 days, PrEP can be initiated at the first visit (same day) 1
  • If no recent test result is available, a rapid point-of-care test should be performed, and PrEP started only if negative 1

Hepatitis B Monitoring

  • For individuals with active HBV infection, careful monitoring of liver function is required when starting or stopping PrEP due to risk of hepatitis flares 1

Implementation Challenges

Despite clear guidelines, adherence to testing protocols in Australia has been suboptimal:

  • Studies show only 35% of MSM receive annual HIV testing as recommended 3
  • Among higher-risk MSM, only 15% receive 6-monthly HIV testing 3

Clinical Pearls

  • Documentation: Always document HIV status before each PrEP prescription renewal
  • Adherence support: Use each follow-up visit to assess and address barriers to PrEP adherence 1
  • Comprehensive prevention: Deliver PrEP as part of a comprehensive prevention package including risk-reduction counseling 2
  • Consider DoxyPEP: For cisgender men who have sex with men and transgender women, doxycycline post-exposure prophylaxis (200mg within 72 hours after condomless sex) can be considered to reduce bacterial STI incidence 2

By following these testing requirements, healthcare providers can ensure safe and effective PrEP provision while monitoring for HIV, STIs, and potential adverse effects of medication.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pre-Exposure Prophylaxis Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.